Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared on LinkedIn:
“Kicking off Lunar New Year with incredible news!
Our paper, ‘Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer,’ has been selected as one of the 100 Editor’s Choice Articles for Q4 2025 by the Journal of Personalized Medicine MDPI.
This achievement reflects a tremendous team effort, with special appreciation to Shipra Gandhi, Sarabjot Pabla, and R.J. Seager for their key contributions.
Feeling grateful, energized, and ready for more impact in 2026!”
Title: Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
Authors: Robert J. Seager, Heidi Ko, Sarabjot Pabla, Maria-Fernanda Senosain, Pawel Kalinski, Erik Van Roey, Shuang Gao, Kyle C. Strickland, Rebecca Ann Previs, Mary K. Nesline, Stephanie Hastings, Shengle Zhang, Jeffrey M. Conroy, Taylor J. Jensen, Marcia Eisenberg, Brian Caveney, Eric A. Severson, Shakti Ramkissoon, Shipra Gandhi
Read the Full Article.
More from Heidi Ko.
